Consistently, in vivo cardiac-specific overexpression of CPT1B via an AAV9 vector with a cardiomyocyte-specific promoter (cTnT) also confirmed that the K321-R mutation of CPT1B protected against endotoxic shock-induced secondary cardiomyopathy. The gene discussed is TNNT2; the disease is cardiomyopathy.